Aromatase, breast cancer and obesity: A complex interaction

Trends in Endocrinology and Metabolism

Volumn 23, Issue 2, 2012, Pages 83-89

  Bulun, Serdar E ^a   Chen, Dong ^a   Moy, Irene ^a   Brooks, David C ^a   Zhao, Hong ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A1 RECEPTOR; AROMATASE; BETA CATENIN; ESTRADIOL; ESTROGEN; FOLLITROPIN; LEPTIN; PROGESTERONE RECEPTOR; PROSTAGLANDIN E2; STEROIDOGENIC FACTOR 1; TESTOSTERONE 17BETA DEHYDROGENASE; WNT11 PROTEIN;

BREAST CANCER; CANCER GROWTH; CANCER RISK; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; ESTROGEN SYNTHESIS; FIBROBLAST; GENE OVEREXPRESSION; HIGH RISK POPULATION; HORMONE ACTION; HUMAN; OBESITY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SUBCUTANEOUS FAT;

ADIPOSE TISSUE; AROMATASE; BREAST; BREAST NEOPLASMS; ESTROGENS; FEMALE; FIBROBLASTS; HUMANS; OBESITY; PARACRINE COMMUNICATION; SIGNAL TRANSDUCTION;

EID: 84856450751     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2011.10.003     Document Type: Review

References (80)

1. Flegal K.M., et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303:235-241.
2. Sutton-Tyrrell K., et al. Reproductive hormones and obesity: 9 years of observation from the Study of Women's Health Across the Nation. Am. J. Epidemiol. 2010, 171:1203-1213.
3. Ziegler R.G., et al. Relative weight, weight change, height, and breast cancer risk in Asian-American women. J. Natl. Cancer Inst. 1996, 88:650-660.
4. Gunter M.J., et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. 2009, 101:48-60.
5. Morimoto L.M., et al. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control 2002, 13:741-751.
6. De Waars F., et al. The biomodal age distribution of patients with mammary carcinoma: evidence for the existence of 2 types of human breast cancer. Cancer 1964, 17:141-151.
7. Gonzalez R.R., et al. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J. Biol. Chem. 2006, 281:26320-26328.
8. Krause S., et al. The microenvironment determines the breast cancer cells' phenotype: organization of MCF7 cells in 3D cultures. BMC Cancer 2010, 10:263.
9. Bulun S.E., et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol. Rev. 2005, 57:359-383.
10. Lin Z., et al. Novel estrogen receptor-alpha binding sites and estradiol target genes identified by chromatin immunoprecipitation cloning in breast cancer. Cancer Res. 2007, 67:5017-5024.
11. Lin Z., et al. Adenosine A1 receptor, a target and regulator of estrogen receptoralpha action, mediates the proliferative effects of estradiol in breast cancer. Oncogene 2010, 29:1114-1122.
12. Chlebowski R.T., et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010, 304:1684-1692.
13. Dressing G.E., et al. Progesterone receptors act as sensors for mitogenic protein kinases in breast cancer models. Endocr. Relat. Cancer 2009, 16:351-361.
14. LaCroix A.Z., et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011, 305:1305-1314.
15. Anderson G.L., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004, 291:1701-1712.
16. Aubuchon M., Santoro N. Lessons learned from the WHI: HRT requires a cautious and individualized approach. Geriatrics 2004, 59:22-26.
17. Bulun S.E., et al. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J. Clin. Endocrinol. Metab. 1993, 77:1622-1628.
18. Cleland W.H., et al. Aromatase activity of membrane fractions of human adipose tissue stromal cells and adipocytes. Endocrinology 1983, 113:2155-2160.
19. Baum M., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139.
20. Key T.J., et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J. Natl. Cancer Inst. 2003, 95:1218-1226.
21. O'Neill J.S., et al. Aromatase activity in adipose tissue from breast quadrants: a link with tumor site. Br. Med. J. 1988, 296:741-743.
22. Bulun S.E., et al. Distribution of aromatase P450 transcripts and adipose fibroblasts in the human breast. J. Clin. Endocrinol. Metab. 1996, 81:1273-1277.
23. Agarwal V.R., et al. Alternatively spliced transcripts of the aromatase cytochrome P450 (CYP19) gene in adipose tissue of women. J. Clin. Endocrinol. Metab. 1997, 82:70-74.
24. Agarwal V.R., et al. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J. Clin. Endocrinol. Metab. 1996, 81:3843-3849.
25. Hotamisligil G.S., et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 1995, 95:2409-2415.
26. Zhao Y., et al. Tumor necrosis factor-alpha stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter I.4. Mol. Endocrinol. 1996, 10:1350-1357.
27. 2-terminal kinase in adipose fibroblasts. Cancer Res. 2007, 67:8914-8922.
28. Santen R. To block estrogen's synthesis or action: that is the question. J. Clin. Endocrinol. Metab. 2002, 87:3007-3012.
29. Baum M., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003, 98:1802-1810.
30. Buzdar A.U., et al. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women. Breast J. 2004, 10:211-217.
31. Bonneterre J., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomized group efficacy and tolerability study. J. Clin. Oncol. 2000, 18:3748-3757.
32. Goss P.E., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 2003, 349:1793-1802.
33. Mouridsen H., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol. 2001, 19:2596-2606.
34. Milla-Santos A., et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: A prospective, randomized, phase III study. Am. J. Clin. Oncol. 2003, 26:317-322.
35. Paridaens R., et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann. Oncol. 2003, 14:1391-1398.
36. Simpson E.R., et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr. Rev. 1994, 15:342-355.
37. Simpson E.R. Sources of estrogen and their importance. J. Steroid Biochem. Mol. Biol. 2003, 86:225-230.
38. Simpson E., et al. Tissue-specific estrogen biosynthesis and metabolism. Ann. N. Y. Acad. Sci. 2001, 949:58-67.
39. Jones M.E., et al. Of mice and men: the evolving phenotype of aromatase deficiency. Trends Endocrinol. Metab. 2006, 17:55-64.
40. Demura M., et al. Regional rearrangements in chromosome 15q21 cause formation of cryptic promoters for the CYP19 (aromatase) gene. Hum. Mol. Genet. 2007, 16:2529-2541.
41. Parakh T.N., et al. Follicle-stimulating hormone/cAMP regulation of aromatase gene expression requires beta-catenin. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:12435-12440.
42. Chen D., et al. JunD and JunB integrate prostaglandin E2 activation of breast cancer-associated proximal aromatase promoters. Mol. Endocrinol. 2011, 25:767-775.
43. Zhou J., et al. Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta. Cancer Res. 2001, 61:2328-2334.
44. Deb S., et al. A novel role of sodium butyrate in the regulation of cancer-associated aromatase promoters I.3 and II by disrupting a transcriptional complex in breast adipose fibroblasts. J. Biol. Chem. 2006, 281:2585-2597.
45. Utsumi T., et al. Presence of alternatively spliced transcripts of aromatase gene in human breast cancer. J. Clin. Endocrinol. Metab. 1996, 81:2344-2349.
46. Zhou C., et al. Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction. J. Steroid Biochem. Mol. Biol. 1996, 59:163-171.
47. Irahara N., et al. Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-alpha, IL-6 and COX-2 mRNAs in human breast cancer. Int. J. Cancer 2006, 118:1915-1921.
48. Sebastian S., et al. Cloning and characterization of a novel endothelial promoter of the human CYP19 (aromatase P450) gene that is up-regulated in breast cancer tissue. Mol. Endocrinol. 2002, 16:2243-2254.
49. Shozu M., et al. Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. N. Engl. J. Med. 2003, 348:1855-1865.
50. Hankinson S., et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. 1999, 90:1292-1299.
51. Huang Z., et al. Dual effects of weight and weight gain on breast cancer risk. JAMA 1997, 278:1407-1411.
52. Chetrite G., et al. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J. Steroid Biochem. Mol. Biol. 2000, 72:23-27.
53. Geisler J., et al. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. J. Steroid Biochem. Mol. Biol. 2000, 72:259-264.
54. van Landeghem A.A., et al. Endogenous concentration and subcellular distribution of androgens in normal and malignant human breast tissue. Cancer Res. 1985, 45:2907-2912.
55. Sasano H., et al. Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. Hum. Pathol. 1994, 25:530-535.
56. Harada N., et al. Tissue-specific expression of the human aromatase cytochrome P450 gene by alternative use of multiple exons I and promoters, and switching of tissue-specific exons I in carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:11312-11316.
57. Reed M.J., et al. Control of aromatase activity in breast cancer cells: the role of cytokines and growth factors. J. Steroid Biochem. Mol. Biol. 1993, 44:589-596.
58. Tekmal R.R., et al. Aromatase overexpression and breast hyperplasia, an in vivo model - continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands. Endocr. Relat. Cancer 1999, 6:307-314.
59. Amin S.A., et al. Paracrine-stimulated gene expression profile favors estradiol production in breast tumors. Mol. Cell. Endocrinol. 2006, 253:44-55.
60. Price T., et al. Determination of aromatase cytochrome P450 messenger ribonucleic acid in human breast tissue by competitive polymerase chain reaction amplification. J. Clin. Endocrinol. Metab. 1992, 74:1247-1252.
61. Santen R.J., et al. Stromal spindle cells contain aromatase in human breast tumors. J. Clin. Endocrinol. Metab. 1994, 79:627-632.
62. Sasano H., et al. Aromatase and 17beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma. J. Clin. Endocrinol. Metab. 1996, 81:4042-4046.
63. Brodie A., et al. Aromatase expression in the human breast. Breast Cancer Res. Treat. 1998, 49(Suppl. 1):S85-S91.
64. Sasano H., et al. Validation of new aromatase monoclonal antibodies for immunohistochemistry: progress report. J. Steroid Biochem. Mol. Biol. 2003, 86:239-244.
65. Ackerman G.E., et al. Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture. J. Clin. Endocrinol. Metab. 1981, 53:412-417.
66. Pauley R.J., et al. Regulated CYP19 aromatase transcription in breast stromal fibroblasts. J. Clin. Endocrinol. Metab. 2000, 85:837-846.
67. Haagensen C.D. Diseases of the Breast 1986, W.B. Saunders Company.
68. Meng L., et al. TNFalpha and IL-11 secreted by malignant breast epithelial cells inhibit adipocyte differentiation by selectively downregulating C/EBPalpha and PPARgamma: mechanism of desmoplastic reaction. Cancer Res. 2001, 61:2250-2255.
69. Coleman R.A., et al. VIII. International Union of Pharmacology. Classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 1994, 46:205-229.
70. Zhao Y., et al. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996, 137:5739-5742.
71. Brueggemeier R.W., et al. Aromatase and cyclooxygenases: enzymes in breast cancer. J. Steroid Biochem. Mol. Biol. 2003, 86:501-507.
72. Clyne C.D., et al. Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in preadipocytes. J. Biol. Chem. 2002, 277:20591-20597.
73. Safi R., et al. Coactivation of liver receptor homologue-1 by peroxisome proliferator-activated receptor gamma coactivator-1alpha on aromatase promoter II and its inhibition by activated retinoid X receptor suggest a novel target for breast-specific antiestrogen therapy. Cancer Res. 2005, 65:11762-11770.
74. Lee Y.K., et al. Phosphorylation of the hinge domain of the orphan nuclear hormone receptor LRH-1 stimulates transactivation. J. Biol. Chem. 2006, 281:7850-7855.
75. Hinshelwood M.M., et al. Expression of LRH-1 and SF-1 in the mouse ovary: localization in different cell types correlates with differing function. Mol. Cell. Endocrinol. 2003, 207:39-45.
76. Krylova I.N., et al. Structural analyses reveal phosphatidyl inositols as ligands for the NR5 orphan receptors SF-1 and LRH-1. Cell 2005, 120:343-355.
77. Sablin E.P., et al. Structural basis for ligand-independent activation of the orphan nuclear receptor LRH-1. Mol. Cell 2003, 11:1575-1585.
78. Chand A.L., et al. Tissue-specific regulation of aromatase promoter II by the orphan nuclear receptor LRH-1 in breast adipose stromal fibroblasts. Steroids 2011, 76:741-744.
79. Brown K.A., et al. Subcellular localization of cyclic AMP-responsive element binding protein-regulated transcription coactivator 2 provides a link between obesity and breast cancer in postmenopausal women. Cancer Res. 2009, 69:5392-5399.
80. Ghosh S., et al. IKKbeta mediates cell shape-induced aromatase expression and estrogen biosynthesis in adipose stromal cells. Mol. Endocrinol. 2009, 23:662-670.